SCHEMBL13627965

SCHEMBL13627965

O=C1/C(=N\O)c2cc(Cl)ccc2N1Cc1cccc(Oc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
ALDH2 P05091 2/20 0.55
ALDH3A1 P30838 2/20 0.55
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA4 P22748 1/20 0.49
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
CHRM5 P08912 1/20 0.45
UCHL3 P15374 1/20 0.44
KDR P35968 1/20 0.44
UCHL1 P09936 1/20 0.44
PRKAG1 P54619 3/20 0.43
PRKAA2 P54646 3/20 0.43
PRKAB1 Q9Y478 3/20 0.43
TP53 P04637 2/20 0.43
CXCR2 P25025 1/20 0.42
FAAH O00519 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
CCR8 P51685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627927 0.89 ALDH3A1 (0.68) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627959 0.88 ALDH1A1 (0.50) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627975 0.87 TRPA1 (0.50) ALDH1A1ALDH3A1CA1CA2CA12
SCHEMBL13910749 0.86 ALDH1A1 (0.58) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627999 0.82 CHRM5 (0.43) ALDH1A1CHRM5TP53FAAHCCR8
SCHEMBL13627932 0.82 CA1 (0.59) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627933 0.82 TP53 (0.53) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627874 0.81 ALDH3A1 (0.56) ALDH1A1ALDH2ALDH3A1CA1CA2
SCHEMBL13627885 0.81 ALDH1A1 (0.54) ALDH1A1ALDH2ALDH3A1CA2CA12
SCHEMBL13627966 0.80 UCHL3 (0.52) ALDH1A1ALDH2ALDH3A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885ALDH2 3451/4885ALDH3A1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.